AGEN
AgenusAGEN
AGEN
About: Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Employees: 316
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
913% more call options, than puts
Call options by funds: $5.42M | Put options by funds: $535K
25% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 20
3.64% less ownership
Funds ownership: 39.0% [Q3] → 35.36% (-3.64%) [Q4]
13% less funds holding
Funds holding: 97 [Q3] → 84 (-13) [Q4]
41% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 29
50% less capital invested
Capital invested by funds: $45.7M [Q3] → $22.8M (-$22.9M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$3
84%
upside
Avg. target
$3
84%
upside
High target
$3
84%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Baird Colleen Kusy 18% 1-year accuracy 2 / 11 met price target | 84%upside $3 | Neutral Maintained | 12 Mar 2025 |
Financial journalist opinion
Based on 6 articles about AGEN published over the past 30 days
Neutral
Business Wire
1 week ago
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus' neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT/BAL), including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poste.
Positive
Zacks Investment Research
1 week ago
Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now
Agenus (AGEN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Neutral
Business Wire
2 weeks ago
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today announced the results of its national Colorectal Cancer in Focus survey, highlighting critical unmet needs and patient priorities in colorectal cancer (CRC) care. Colorectal cancer remains the second leading cause of cancer-related deaths worldwide and places an enormous burden on individuals, their families and loved ones, and the healthcare system.
Neutral
Seeking Alpha
3 weeks ago
Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript
Agenus Inc. (NASDAQ:AGEN ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations, Corporate Development Garo Armen - Chairman and Chief Executive Officer Christine Klaskin - Vice President, Finance and Principal Financial and Accounting Officer Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.
Negative
Zacks Investment Research
3 weeks ago
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
Agenus (AGEN) came out with a quarterly loss of $2.04 per share versus the Zacks Consensus Estimate of a loss of $2.36. This compares to loss of $2.60 per share a year ago.
Neutral
Business Wire
3 weeks ago
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program. "In line with our strategic objectives, we significantly reduced our annualized operational burn rate. We anticipat.
Neutral
Business Wire
1 month ago
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy. Agenus is advancing a robust clinical pipeline targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, tumor microenvironment conditioning agents and cell therapies (via MiNK Therapeutics). Our most advanced antibody candidates, botensi.
Neutral
Business Wire
1 month ago
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced participation in a panel discussion at the B. Riley Securities Precision Oncology & Radiopharma Investor Conference that will take place on Friday, February 28th in New York. Panel Discussion Details: Speaker: Robin Taylor, Ph.D., Chief Commercial Officer Topic: “What It Takes to Move the Needle in Improving Responses in Colorectal Cancer”' Date: 02/28/2025 Time: 1:00-2:00 p.m. ET Loc.
Neutral
Business Wire
1 month ago
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 11th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register her.
Neutral
Business Wire
1 month ago
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles, California. The oral presentation highlights translational data from the ongoing Phase 2 study evaluating botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1) in combination with MiNK Therapeutics' agenT-797, an allogeneic invariant natural killer T (iNKT).
Charts implemented using Lightweight Charts™